Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tim Cooley, Kevin Krenzke, Ardy Arianpour

Premium

MolecularHealth has added two new members to its US executive team: Tim Cooley and Kevin Krenzke.

Cooley will be senior VP of IT at MolecularHealth. He previously spent 15 years at Eli Lilly, where he held various positions, including director of IT. Krenzke will be senior VP of finance at MolecularHelath. He joins the firm after holding leaderships roles at McKesson Specialty Health and US Oncology.

The new additions to the MolecularHealth team come as the company is readying to launch TreatmentMAP, a cancer treatment decision support tool, in the first quarter.


Ardy Arianpour has joined Pathway Genomics as chief strategy officer, the company said this week.
Arianpour most recently was senior VP of business development at Ambry Genetics, and during his 13-year career in the biotech sector he also has worked in senior sales and business development roles at Clinical Data, Cogenics, and Eurogentec North America. In his new post, Arianpour will lead the San Diego-based company's global strategy, strategic planning, and partnership activities.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.